Phase I Study Evaluating the Combination of Lapatinib (GW572016; NSC-727989; IND-75,093) and Everolimus (RAD001; NSC-733504; IND-75,093) in Patients with Advanced Solid Tumors

Pts must have cytologically or pathologically cancer of advanced stage; measurable or non-measurable disease; Pts with brain mets must be on stabe or decreasing corticosteroids and seizure free for 30 days; Pts with untreated brain mets are not eligible; Zubrod PS 0-2; 18 yrs of age or older; ANC >=1.5; Platelets >=100; SGOT/SGPT <= 2.5xIULN; Bili <= IULN; Pts with liver mets must have SGOT/SGPT <= 5xIULN; Patients must not have current active hepatic or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones); adequate renal function (serum creatinine <= IULN; or measured creatinine > 60 mL/min; or estimated creatinine > 60 mL/min); cardiac ejection fraction within inst. range of normal; pts must be able to swallow meds.; pts. with feeding tubes are not eligible; no prior treatment with study drugs; no major surgery, chemo or radiotherapy within 14 days; no nitrosoureas or mitomycin c within 42 days; no investigational agents within 28 days; Pts known to be HIV-pos. are not eligible; Pts that are pregnant or nursing are not eligible; Pts with uncontrolled intercurrent illness are not eligible